Benzinga | May 19, 2021 08:03AM EDT

Histogen Partner Amerimmune Highlights Publication Of Emricasan Data In Journal of the European Academy of Allergy and Clinical Immunology

Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function and its partner, Amerimmune, LLC, today reported the publication of the potential utility of emricasan in COVID-19 in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology.